Carnegie Investment Counsel Acquires 3,193 Shares of Eli Lilly and Company $LLY

Key Points

• Carnegie Investment Counsel increased its stake in Eli Lilly and Company by 34.0%, acquiring an additional 3,193 shares during the second quarter, bringing their total holdings to 12,572 shares worth $9.8 million.
• Insider transactions included Director Gabrielle Sulzberger purchasing 117 shares for a total of $75,018, and Director J Erik Fyrwald acquiring 1,565 shares valued at over $1 million.
• Eli Lilly reported strong quarterly earnings with $6.31 earnings per share, surpassing estimates and achieving a net margin of 25.91%, indicating a 37.6% year-over-year revenue increase.

Carnegie Investment Counsel lifted its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 34.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 12,572 shares of the company's stock after acquiring an additional 3,193 shares during the period. Carnegie Investment Counsel's holdings in Eli Lilly and Company were worth $9,800,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in LLY. PNC Financial Services Group Inc. lifted its holdings in shares of Eli Lilly and Company by 97.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company's stock worth $83,669,349,000 after acquiring an additional 50,002,551 shares during the period. Nuveen LLC bought a new stake in shares of Eli Lilly and Company during the 1st quarter worth approximately $4,613,912,000. Vanguard Group Inc. lifted its holdings in shares of Eli Lilly and Company by 6.7% during the 1st quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company's stock worth $65,432,218,000 after acquiring an additional 4,975,395 shares during the period. Cohen Investment Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 7,975.5% during the 1st quarter. Cohen Investment Advisors LLC now owns 783,651 shares of the company's stock worth $647,225,000 after acquiring an additional 773,947 shares during the period. Finally, Assenagon Asset Management S.A. lifted its holdings in shares of Eli Lilly and Company by 106.8% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,481,031 shares of the company's stock worth $1,154,508,000 after acquiring an additional 765,010 shares during the period. Institutional investors own 82.53% of the company's stock.

Insider Activity at Eli Lilly and Company

In other news, Director Gabrielle Sulzberger acquired 117 shares of the firm's stock in a transaction dated Tuesday, August 12th. The stock was bought at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the transaction, the director directly owned 2,703 shares in the company, valued at $1,733,109.54. This represents a 4.52% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director J Erik Fyrwald acquired 1,565 shares of the firm's stock in a transaction dated Tuesday, August 12th. The shares were purchased at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the transaction, the director owned 74,578 shares of the company's stock, valued at $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired a total of 4,514 shares of company stock valued at $2,894,841 over the last 90 days. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Price Performance

LLY stock opened at $825.86 on Friday. The company has a fifty day moving average price of $768.01 and a 200-day moving average price of $768.14. The company has a market capitalization of $781.65 billion, a P/E ratio of 53.98, a PEG ratio of 1.18 and a beta of 0.47. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $935.63. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company's revenue for the quarter was up 37.6% on a year-over-year basis. During the same quarter last year, the firm earned $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on LLY. Leerink Partners reaffirmed a "market perform" rating and set a $715.00 price target on shares of Eli Lilly and Company in a report on Thursday, August 7th. The Goldman Sachs Group increased their price objective on shares of Eli Lilly and Company from $876.00 to $879.00 and gave the company a "buy" rating in a research note on Friday, October 10th. BMO Capital Markets increased their price objective on shares of Eli Lilly and Company from $840.00 to $930.00 and gave the company an "outperform" rating in a research note on Monday, October 20th. Erste Group Bank raised shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Tuesday, October 14th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating for the company in a research note on Tuesday, September 16th. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $938.61.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.